# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch r...
Beyfortus is anticipated to be available during the upcoming 2024-2025 RSV season.
The trial included patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-m...
The trial included patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actiona...
The CRL did not request additional analysis or reanalysis of the Phase 3 CHAMPION-NMOSD trial data and did not raise concerns...